Superantigens of Staphylococcus Aureus Colonization in Atopic Dermatitis and Treatment Efficacy of Oral Cefuroxim in Vietnamese Patients by Van, Tro Chau et al.
 
Open Access Maced J Med Sci electronic publication ahead of print,  
published on January 27, 2019 as https://doi.org/10.3889/oamjms.2019.061 
_______________________________________________________________________________________________________________________________ 
Open Access Maced J Med Sci.                                                                                                                                                                                                          1 
 
ID Design Press, Skopje, Republic of Macedonia 
Open Access Macedonian Journal of Medical Sciences. 
Special Issue: Vietnamese Dermatology 
https://doi.org/10.3889/oamjms.2019.061 
eISSN: 1857-9655 
Clinical Science 
 
 
  
 
Superantigens of Staphylococcus Aureus Colonization in Atopic 
Dermatitis and Treatment Efficacy of Oral Cefuroxim in 
Vietnamese Patients 
 
 
Tro Chau Van
1
, Thang Nguyen Tat
2
, Anh Tran Lan
3
, Thuong Nguyen Van
3
, Marco Gandolfi
4*
, Francesca Satolli
4
, Claudio 
Feliciani
4
, Michael Tirant
5,6
, Aleksandra Vojvodic
7
, Torello Lotti
5
 
 
1
Department of Dermatology, Pham Ngoc Thach University of Medicine, Vietnam; 
2
Departments of Dermatology, University 
of Medicine and Pharmacy, Ho Chi Minh City, Vietnam; 
3
Department of Dermatology, Hanoi Medical University, Hanoi, 
Vietnam; 
4
Unit of Dermatology, University of Parma, Parma, Italy; 
5
University of Rome G. Marconi, Rome, Italy; 
6
Psoriasis 
Eczema Clinic, Melbourne, Australia; 
7
Department of Dermatology and Venereology, Military Medical Academy of Belgrade, 
Belgrade, Serbia 
 
Citation: Van TC, Tat TN, Lan AT, Nguyen Van T, 
Gandolfi M, Satolli F, Feliciani C, Tirant M, Vojvodic A, 
Lotti T. Superantigens of Staphylococcus Aureus 
Colonization in Atopic Dermatitis and Treatment Efficacy 
of Oral Cefuroxim In Vietnamese Patients. Open Access 
Maced J Med Sci. 
https://doi.org/10.3889/oamjms.2019.061 
Keywords: Atopic dermatitis; Superantigen; S. aureus 
*Correspondence: Marco Gandolfi. Unit of Dermatology, 
University of Parma, Parma, Italy. E-mail: 
marco.gandolfi5@gmail.com 
Received: 02-Jan-2019; Revised: 16-Jan-2019; 
Accepted: 17-Jan-2019; Online first: 20-Jan-2019 
Copyright: © 2019 Tro Chau Van, Thang Nguyen Tat, 
Anh Tran Lan, Thuong Nguyen Van, Marco Gandolfi, 
Francesca Satolli, Claudio Feliciani, Michael Tirant, 
Aleksandra Vojvodic, Torello Lotti. This is an open-access 
article distributed under the terms of the Creative 
Commons Attribution-NonCommercial 4.0 International 
License (CC BY-NC 4.0) 
Funding: This research did not receive any financial 
support 
Competing Interests: The authors have declared that no 
competing interests exist 
 
 
 
 
 
 
Abstract 
BACKGROUND: Atopic dermatitis (AD) is a common, chronic, relapsing, genetically determined inflammatory 
skin disorder. Staphylococcus aureus (S. aureus) plays an important role in the pathogenesis of AD. Atopic skin is 
susceptible to infection with S. aureus.  
AIM: This study was aimed to compare the skin S. aureus colonisation status and its secretion of superantigens in 
adult AD and healthy subjects and to evaluate the efficacy of two treatment regimens (oral cefuroxime plus topical 
betamethasone dipropionate 0.05% versus topical betamethasone dipropionate 0.05%) in AD patients.  
METHODS: A group of 128 AD and 40 healthy subjects were recruited in this study and treatment efficacy was 
assessed by the SCORAD score.  
RESULTS: S. aureus was found in skin lesions in 83.8% of AD patients while only 37.5% of healthy subjects 
possessed this kind of bacteria in the external nares (p < 0.001). Superantigen production was more common in 
S. aureus strains isolated from AD than the control group (58.6% versus 6.6%, p = 0.0006) and staphylococcal 
enterotoxin B was predominant (88.89%). 68 AD patients who had positive cultures with S. aureus were included 
in a clinical therapeutic trial. The isolated bacteria were all sensitive to cefuroxime. Patients were randomised to 
receive either oral cefuroxime 500 mg b.i.d. Plus topical betamethasone dipropionate 0.05% twice daily for 2 
weeks (so-called group 1, 36 patients) or only topical betamethasone dipropionate 0.05% twice daily for 2 weeks 
(so-called group 2, 32 patients). The mean SCORAD scores of group 1 at baseline and after 1 and 2 weeks of 
treatment were 44.61, 26.69 and 16.61, respectively. The corresponding values for group 2 were 43.03, 32.53 
and 23.41, respectively.  
CONCLUSION: The reduction in SCORAD scores was significantly higher in group 1 than group 2 in comparison 
to the baseline value of each study group (p = 0.003 after 1 week and p < 0.001 at the end of treatment). 
 
 
 
 
 
 
 
Introduction 
 
Atopic dermatitis is a common chronic 
inflammatory skin condition. The prevalence varies 
from 10% to 20% of children. The aetiology and 
pathogenesis of AD have not been completely 
understood, leading to many problems in its 
management. High recurrence rates contribute to 
increasing the prevalence of AD.  
In the late 20
th
 century, Cork [1], Abeck [2], 
and Shuichi [3] found that S. aureus plays a very 
important role in the pathogenesis of AD through the 
production of superantigens including staphylococcal 
enterotoxins A and B, and toxic shock syndrome 
toxin-1 [4], [5], [6]. These superantigens penetrate the 
skin barrier and contribute to the persistence and 
exacerbation of skin inflammation through the 
stimulation of massive T cells [7], [8]. 
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Materials and Methods 
 
Study populations: 128 AD patients were 
enrolled in our study during their visits to the Hospital 
of Dermato-Venereology in Ho Chi Minh City from 
August 2010 to August 2012. There was no selection 
of patients by gender, localisation and severity of 
lesions. Voluntarily informed consents in writing were 
obtained from all participants. AD was diagnosed 
according to Hanifin and Rajka’s criteria, and AD 
severity was based on the SCORAD index. Clinical 
symptoms and SCORAD scores were regularly 
monitored at the end of week 1 and 2, and the culture 
of skin lesions was carried on at the end of week 2. 
The control group consisted of patients without 
personal or family history of skin or allergic diseases 
who visited the Dermatological Outpatient Clinic for 
other reasons during the same period.  
AD patients were all over 12 years old and 
didn’t have any infected skin lesions. Those who had 
positive cultures with S. aureus were recruited in a 
clinical therapeutic trial. All isolated bacteria were 
sensitive to cefuroxime on the antimicrobial 
susceptibility test. Patients were equally randomised 
to receive either oral cefuroxime 500 mg b.i.d. Plus 
topical betamethasone dipropionate 0.05% twice daily 
for 2 weeks (so-called group 1) or only topical 
betamethasone dipropionate 0.05% twice daily for 2 
weeks (so-called group 2). A total of 74 AD patients 
were eligible for this clinical trial (37 patients in each 
group).  
Exclusion criteria included treatment with 
topical antibiotics in the past two weeks; oral or 
intravenous antibiotic treatment in the previous 4 
weeks; presence of severe heart, liver, lung diseases, 
or immunodeficient condition (AIDS, diabetes mellitus, 
utilization of immunosuppressive drugs...), pregnancy 
or breastfeeding status; history of side-effects related 
to the use of corticosteroids (skin atrophy, 
vasodilation, hirsutism); allergy to study drugs (either 
betamethasone dipropionate 0.05% or cefuroxime); 
not adherence to treatment protocol (one patient in 
group 1 and five patients in group 2). Therefore, 36 
patients in group 1 and 32 patients in group 2 gave 
the final data for analysis.  
Isolation of S. aureus and identification of 
staphylococcal superantigens: S. aureus was cultured 
and identified from new skin lesions in AD patients 
and skin area around the nostrils in healthy subjects. 
Staphylococcal superantigens were tested by 
multiplex PCR (Polymerase Chain Reaction). 
Antimicrobial susceptibility tests were performed using 
the broth microdilution method for antibiotics: 
cefuroxime, ampicillin, ciprofloxacin, doxycycline, 
erythromycin, linezolid, tetracycline and vancomycin. 
Statistics: Data were analysed by the EpiInfo 
software (version 2002). Qualitative variables were 
presented as frequency and percentage while 
quantitative variables as mean and SD. Categorical 
variables were compared using chi-squared or 
Fisher’s exact test, as appropriate. RR and 95%CI 
(confidence interval) were also used to measure 
differences in the relationship of results. One-way 
ANOVA test was used to compare average scores of 
clinical symptoms and SCORAD index in two groups 
at baseline, after 1, 2 weeks of treatment. A p-value < 
0.05 was considered to be statistically significant. 
 
 
Results 
 
A group of 128 AD patients consisted of 
58.6% of males and 41.5% of females, mean age: 
37.65 ± 14.09. Clinical manifestations (in decreasing 
order of frequency) included itching (100%), dry skin 
(78.91%), insomnia (75%), non-specific hand 
dermatitis (57.81%), cheilitis (47.56%), anterior neck 
folds (42.18%), white dermographism (40.62%), 
orbital darkening (26.56%), Dennie Morgan infraorbital 
folds (21.09%), pityriasis alba (18.75%), keratosis 
pilaris (18.75%), ichthyosis vulgaris (7.81%), nipple 
eczema (3.9%).  
 
Figure 1: S. aureus was more commonly isolated from skin lesions 
in AD patients than on the perinotrils of healthy subjects (< 0.001, 
RR = 2.17, 95% CI 1.44-3.26) 
 
The mean SCORAD score was 12.35 ± 
40.55. AD severity was categorised as moderate in 
44.53%, severe in 28.12%, and mild in 27.34% of 
patients. The rates of positive cultures with S. aureus 
in AD patients and healthy subjects were shown in 
figure 1 and the rates of S. aureus strains that secrete 
superantigens were shown in Figure 2. 
 
Figure 2: Superantigens were more commonly found from S. 
aureus strains isolated from AD patients than healthy subjects (p = 
0.0006, RR = 8.65, 95% CI 1.29-57.9) 
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The efficacy of 2 treatment regimens was 
demonstrated in Table 1. 
Table 1: Comparison of the therapeutic effect of the SCORAD 
index 
SCORAD scores 
(Mean ± SD) 
Group 1 Group 2 P values 
At baseline 44.61 ± 8.34 43.03 ± 12.98 0.55 
At the end of week 1 26.69 ± 6.05 32.53 ± 9.31  
At the end of week 2 16.61 ± 3.85 23.41 ± 7.49  
The difference in SCORAD scores 
Between baseline and end of week 1 -17.92 -10.5 0.003 
Between baseline and end of week 2 -28 -19.62 < 0.001 
 
After 2 weeks of treatment, 91.7% of group-1 
patients achieved complete S. aureus elimination 
(negative culture) versus only 21.88% of group-2 
patients (p < 0.001, RR = 5.1, 95% CI 2.57-10.12).  
 
 
Discussion 
 
Our study confirms that the proportion of S. 
aureus colonisation in AD patients was significantly 
higher than that in healthy subjects (p < 0.001, RR = 
2.17, 95% CI 1.44 – 3.26), which is by other studies in 
the world [2], [3], [7]. In 1997, Goh [9] conducted a 
similar study on 33 AD patients in Singapore, showing 
that the rates of positive S. aureus detection were 
89% in lesion areas, 42% in their healthy skin area, 
55% in their outside nostril area, which were 
considerably higher than those in healthy group (5% 
in healthy skin area and 35% in outside nostril area).  
There were 119 samples positive with S. 
aureus, including 104 samples taken from skin lesions 
of AD patients and 15 samples from the outside nostril 
of control subjects. All positive samples were tested 
by real-time PCR technique to find superantigen-
encoding gene segments. Of 104 samples harvested 
from lesion areas, 60 samples were found to have 
superantigen-encoding genes, which was equivalent 
to 57.69%, whereas there was only 1 sample from 
healthy subjects having evidence of superantigen-
encoding genes, which was equivalent to 6.67% (p = 
0.0006, RR = 8.65; 95%CI 1.29 – 57.9). According to 
Breuer [9], the proportion of superantigen detection 
implemented by Latex methodology was 31%. In 
McFadden’s study [10], 65% of S. aureus strains 
isolated from lesion areas of AD patients secrete 
superantigens.  
The treatment efficacy between the two 
groups was assessed by the SCORAD index. Mean 
SCORAD scores at baseline were comparable 
between group 1 and 2 (p = 0.55). At the end of week 
1, mean SCORAD scores decreased to 26.69 ± 6.05 
(difference in-17.92 points) in group 1 and 32.53 ± 
9.31 (difference in-10.05 points) in group 2. At the end 
of week 2, mean SCORAD scores continued to 
decrease to 16.61 ± 3.85 (difference in -28 points from 
baseline) in group 1, and 23.41 ± 7.49 (difference in -
19.62 points from baseline) in group 2. The extent of 
SCORAD reduction within each group was statistically 
significant. SCORAD reduction was significantly 
greater in group 1 than group 2 either at the end of 
week 1 or week 2 (p = 0.003 and p < 0.001, 
respectively), which indicated that oral antibiotics in 
combination with topical corticosteroids lead to a 
higher decrease in SCORAD index compared to 
merely topical corticosteroids. This finding is in line 
with Boguniewicz’s study [11]. 
The therapeutic regimen that associates oral 
antibiotics and topical corticosteroids also had a 
significantly higher rate of S. aureus elimination at the 
end of treatment (91.7% in group 1 versus 21.88% in 
group 2, p < 0.001, RR = 5.1, 95%CI 2.57 – 10.12). 
This finding is also in consistency with Weinberg’s 
study [12].  
 In conclusion, S. aureus is the predominant 
pathogen among patients with AD, colonising much 
more frequently in AD patients than healthy people. 
S.aureus in AD patients also tends to produce 
superantigens much more frequently than healthy 
people. The oral cefuroxime combination with 
betamethasone dipropionate 0,05% is more 
efficacious than betamethasone dipropionate 0.05% 
alone in the treatment of AD patients in the first two 
weeks. 
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